GlaxoSmithKline (GSK) Announces Divestiture of non-Core Assets to Aspen
- Wall Street falls ahead of inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- Synergy Pharma (SGYP) Trulance (Plecanatide) Approved by FDA
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
GlaxoSmithKline (NYSE: GSK) announces a series of agreements with Aspen aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
GSK will divest its anaesthesia portfolio to Aspen for £180 million plus milestones of up to £100 million. In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK’s remaining thrombosis business in certain retained markets.
The agreements announced today are subject to the relevant anti-trust and regulatory clearances.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Federal Judge to Block Anthem (ANTM), Cigna Corp. (CI) Merger - NYP
- Aon plc (AON) Ticks Higher on Plans to Sell Benefits Outsourcing Unit
- Exclusive: Aon nears $4.5 billion sale of benefits outsourcing unit - sources
Create E-mail Alert Related CategoriesCorporate News, Mergers and Acquisitions, Spinoffs
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!